EUVIMEDSkopri EUVIMED
Crossref

Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors

Ankit Kumar Singh, Vineet Prajapati, Vimlendu Kumar Sah, Adarsh Kumar, Amandeep Singh Kalsi, Prateek Pathak, Habibullah Khalilullah, Amita Verma iD, Pradeep Kumar

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70179 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2025. Written by Ankit Kumar Singh and 8 co-authors. Institution: Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India. Major MEDLINE topics: Proto-Oncogene Proteins B-raf, Sulfonamides, Antineoplastic Agents, Drug Design. 28 references. Funded by: Science and Engineering Research Board, Indian Council of Medical Research, Department of Science and Technology, Ministry of Science and Technology, India.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

BRAF is one of the most commonly mutated oncogenes in human cancers. More than 90% of BRAF mutations are associated with malignant melanoma. Given the pivotal role of BRAF V600E/WT mutations in melanoma progression and therapy resistance, our study focused on the design of phenyl‐substituted pyrimidin‐benzenesulfonamide hybrids in the [αC‐OUT/DFG‐IN] conformation, inspired by previously synthesized molecules structurally related to FDA‐approved BRAF inhibitors. A total of ten derivatives were synthesized, and their ADME‐T properties, in silico binding affinities, in vitro cytotoxic activities against a melanoma cell line and BRAF V600E/WT kinase assay were thoroughly evaluated. All compounds exhibit selective and stronger affinity for the BRAF V600E mutant over the wild‐type BRAF protein and also adhere to Lipinski's Rule of Five. Overall, both computational and biological evaluations support that the synthesized compounds, particularly VA03 , exhibit greater potency and selectivity toward the BRAF V600E mutant protein. Furthermore, the presence of electron‐withdrawing groups at the R 1 position appears to significantly enhance the cytotoxic activity of these derivatives.

Subjects

MeSH terms (MEDLINE)

Proto-Oncogene Proteins B-rafSulfonamidesAntineoplastic AgentsDrug DesignProtein Kinase InhibitorsPyrimidinesHumansMolecular Docking SimulationCell Line, TumorStructure-Activity RelationshipBenzenesulfonamidesMelanomaMutation

Author keywords

ADME‐TBRAFV600E/WTcytotoxicitymelanomamolecular dockingαC‐OUT/DFG‐IN

Substances

Proto-Oncogene Proteins B-rafSulfonamidesAntineoplastic AgentsProtein Kinase InhibitorsPyrimidinesBRAF protein, humanBenzenesulfonamides

Authors and institutions

  • Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India.
  • Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, Uttar Pradesh, India.
  • Department of Pharmaceutical Analysis, Quality Assurance and Pharmaceutical Chemistry, School of Pharmacy, GITAM (Deemed to Be University), Hyderabad, Telangana, India.
  • Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.

ORCID profiles: Amita Verma

Funding

  • Science and Engineering Research Board
  • Indian Council of Medical Research
  • Department of Science and Technology, Ministry of Science and Technology, India

Cite

APA

Singh, A. K., Prajapati, V., Sah, V. K., Kumar, A., Kalsi, A. S., Pathak, P., Khalilullah, H., Verma, A., & Kumar, P. (2025). Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70179

Vancouver

Singh AK, Prajapati V, Sah VK, Kumar A, Kalsi AS, Pathak P, et al. Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70179

BibTeX
@article{Singh2025,
  author = {Singh, Ankit Kumar and Prajapati, Vineet and Sah, Vimlendu Kumar and Kumar, Adarsh and Kalsi, Amandeep Singh and Pathak, Prateek and Khalilullah, Habibullah and Verma, Amita and Kumar, Pradeep},
  title = {Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70179}
}
Start for free →